Genus (LON:GNS – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Berenberg Bank in a report issued on Tuesday, Digital Look reports. They currently have a GBX 3,350 target price on the stock. Berenberg Bank’s price target suggests a potential upside of 44.65% from the company’s previous close.
Genus Stock Performance
Genus stock opened at GBX 2,316 on Tuesday. Genus has a fifty-two week low of GBX 1,943 and a fifty-two week high of GBX 3,220. The stock’s 50 day simple moving average is GBX 2,231.55 and its two-hundred day simple moving average is GBX 2,277.89. The company has a debt-to-equity ratio of 14.02, a quick ratio of 1.08 and a current ratio of 2.22. The stock has a market cap of £1.53 billion, a price-to-earnings ratio of 5.45, a PEG ratio of 2.87 and a beta of 0.91.
Genus (LON:GNS – Get Free Report) last announced its earnings results on Thursday, September 10th. The company reported GBX 110.30 earnings per share (EPS) for the quarter. Genus had a return on equity of 44.90% and a net margin of 43.35%. As a group, analysts expect that Genus will post 70.96 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Genus news, insider Jorgen Kokke sold 50,236 shares of the stock in a transaction on Monday, September 14th. The stock was sold at an average price of GBX 2,151, for a total value of £1,080,576.36. 0.71% of the stock is currently owned by insiders.
Genus Company Profile
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.
Further Reading
- Five stocks we like better than Genus
- Could a Trucking Squeeze Become J.B. Hunt’s Biggest Edge?
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.
